286 related articles for article (PubMed ID: 16260062)
1. GASepo-a software solution for quantitative analysis of digital images in Epo doping control.
Bajla I; Holländer I; Minichmayr M; Gmeiner G; Reichel Ch
Comput Methods Programs Biomed; 2005 Dec; 80(3):246-70. PubMed ID: 16260062
[TBL] [Abstract][Full Text] [Related]
2. Improvement of band segmentation in Epo images via column shift transformation with cost functions.
Stolc S; Bajla I
Med Biol Eng Comput; 2006 Apr; 44(4):257-74. PubMed ID: 16937167
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of images in erythropoietin doping control.
Bajla I; Holländer I; Gmeiner G; Reichel Ch
Med Biol Eng Comput; 2005 May; 43(3):403-9. PubMed ID: 16035230
[TBL] [Abstract][Full Text] [Related]
4. Procedures for monitoring recombinant erythropoietin and analogues in doping control.
Segura J; Pascual JA; Gutiérrez-Gallego R
Anal Bioanal Chem; 2007 Aug; 388(7):1521-9. PubMed ID: 17516052
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin (EPO) immunoaffinity columns--a powerful tool for purifying EPO and its recombinant analogues.
Dehnes Y; Lamon S; Lönnberg M
J Pharm Biomed Anal; 2010 Dec; 53(4):1028-32. PubMed ID: 20656433
[TBL] [Abstract][Full Text] [Related]
6. Doping in the recombinant era: strategies and counterstrategies.
Azzazy HM; Mansour MM; Christenson RH
Clin Biochem; 2005 Nov; 38(11):959-65. PubMed ID: 16286094
[TBL] [Abstract][Full Text] [Related]
7. IEF pattern classification-derived criteria for the identification of epoetin-delta in urine.
Lamon S; Boccard J; Sottas PE; Glatz N; Wuerzner G; Robinson N; Saugy M
Electrophoresis; 2010 Jun; 31(12):1918-24. PubMed ID: 20564689
[TBL] [Abstract][Full Text] [Related]
8. Testing for recombinant erythropoietin.
Delanghe JR; Bollen M; Beullens M
Am J Hematol; 2008 Mar; 83(3):237-41. PubMed ID: 17918255
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin doping. A comment.
Remacha AF
Haematologica; 2000; 85(E-letters):E04. PubMed ID: 11114819
[No Abstract] [Full Text] [Related]
10. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry.
Yu NH; Ho EN; Wan TS; Wong AS
Anal Bioanal Chem; 2010 Apr; 396(7):2513-21. PubMed ID: 20148243
[TBL] [Abstract][Full Text] [Related]
11. Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis.
Lasne F; Thioulouse J; Martin L; de Ceaurriz J
Electrophoresis; 2007 Jun; 28(12):1875-81. PubMed ID: 17503402
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport.
Abellan R; Ventura R; Pichini S; Remacha AF; Pascual JA; Pacifici R; Di Giovannandrea R; Zuccaro P; Segura J
J Pharm Biomed Anal; 2004 Sep; 35(5):1169-77. PubMed ID: 15336362
[TBL] [Abstract][Full Text] [Related]
13. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs.
Cazzola M
Haematologica; 2000 Jun; 85(6):561-3. PubMed ID: 10870110
[No Abstract] [Full Text] [Related]
14. A high-throughput test to detect C.E.R.A. doping in blood.
Lamon S; Giraud S; Egli L; Smolander J; Jarsch M; Stubenrauch KG; Hellwig A; Saugy M; Robinson N
J Pharm Biomed Anal; 2009 Dec; 50(5):954-8. PubMed ID: 19625154
[TBL] [Abstract][Full Text] [Related]
15. "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable.
Lasne F; Martin L; de Ceaurriz J; Larcher T; Moullier P; Chenuaud P
Mol Ther; 2004 Sep; 10(3):409-10. PubMed ID: 15336641
[No Abstract] [Full Text] [Related]
16. Detection of erythropoiesis-stimulating agents in human anti-doping control: past, present and future.
Leuenberger N; Reichel C; Lasne F
Bioanalysis; 2012 Jul; 4(13):1565-75. PubMed ID: 22831473
[TBL] [Abstract][Full Text] [Related]
17. Effects of high intensity exercise on isoelectric profiles and SDS-PAGE mobility of erythropoietin.
Voss S; Lüdke A; Romberg S; Schänzer E; Flenker U; deMarees M; Achtzehn S; Mester J; Schänzer W
Int J Sports Med; 2010 Jun; 31(6):367-71. PubMed ID: 20419620
[TBL] [Abstract][Full Text] [Related]
18. Beyond sports-doping headlines: the science of laboratory tests for performance-enhancing drugs.
Hatton CK
Pediatr Clin North Am; 2007 Aug; 54(4):713-33, xi. PubMed ID: 17723873
[TBL] [Abstract][Full Text] [Related]
19. Rogue athletes and recombinant DNA technology: challenges for doping control.
Azzazy HM; Mansour MM
Analyst; 2007 Oct; 132(10):951-7. PubMed ID: 17893796
[TBL] [Abstract][Full Text] [Related]
20. Applications and biomonitoring issues of recombinant erythropoietins for doping control.
Tsitsimpikou C; Kouretas D; Tsarouhas K; Fitch K; Spandidos DA; Tsatsakis A
Ther Drug Monit; 2011 Feb; 33(1):3-13. PubMed ID: 21099742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
